These two weeks were unusually busy for things that are not studies. A professional association moved to change the name of the condition, Canada began training physicians to diagnose it inside a live patient clinic, and one of the two competing international organizations in the field launched a patient-facing campaign that states positions many patients will find surprising.
None of this is new evidence. All of it affects what patients are told, what clinicians are taught, and in some countries who gets treated.
An international association wants to rename the condition
On 10 September the board of the International Lipoedema Association unanimously endorsed renaming lipoedema to lipalgia syndrome. The reasoning is that the word oedema implies fluid and lymphatic dysfunction, and the association holds that this is not what defines the disease. Lipalgia, from the Greek words for fat and pain, puts pain at the center instead.
The proposal itself is old. It came out of the 2020 European consensus document led by Tobias Bertsch and colleagues, and several services have already adopted it. Lymphoedema Wales uses it, as does Lymphoedema Network Northern Ireland, the Földi Clinic in Germany and Klose Training in the United States. What changed on 10 September is that an international professional body endorsed it as an organization.
Nothing changes today for diagnosis, coding or access to treatment. ICD terminology is unaffected, and the association says so itself.
The claim that needs care is the statement that the evidence is overwhelmingly clear that this is not a lymphatic disorder. Lymphatic and microvascular abnormalities have been found in at least some lipedema cohorts, and whether they are cause, consequence or disease modifier is still open. The defensible version is that oedema is not sufficient to define the disease, which is a narrower statement than removing lymphatic biology from the picture.
Why this is a dispute rather than a decision
The field has been split into two international organizations since the 2020 consensus document, and that is the context missing from most coverage of the renaming.
The ILA supports the 2020 document and its terminology. The Lipedema World Alliance, founded in 2022 and led by Sandro Michelini with Karen Herbst as vice president, does not. It published its own Delphi consensus in Nature Communications in January 2026, with 59 statements agreed by specialists from 19 countries, and that document uses lipedema throughout.
